Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2018 Jun;9(3):444-452.
doi: 10.1002/jcsm.12292. Epub 2018 Mar 14.

Megestrol acetate for cachexia-anorexia syndrome. A systematic review

Vicente Ruiz-García  1 , Eduardo López-Briz  2 , Rafael Carbonell-Sanchis  3 , Sylvia Bort-Martí  4 , José Luis Gonzálvez-Perales  5
Affiliations
Meta-Analysis

Megestrol acetate for cachexia-anorexia syndrome. A systematic review

Vicente Ruiz-García et al. J Cachexia Sarcopenia Muscle. 2018 Jun.

Abstract

In 1993, megestrol acetate (MA) was approved by the US Food and Drug Administration for the treatment of anorexia, cachexia, or unexplained weight loss in patients with acquired immunodeficiency syndrome. The mechanism by which MA increases appetite is unknown, and its effectiveness for anorexia and cachexia in neoplastic, elderly, and acquired immunodeficiency syndrome patients is under investigation. This is an updated version of a Cochrane systematic review first published in 2005 and later updated in 2013 entitled 'Megestrol acetate for the treatment of anorexia-cachexia syndrome'. MA vs. placebo: in studies where MA was compared with placebo, the overall results showed that MA patients gained weight (mean difference, MD 2.25 kg, 95% CI [1.19, 3.3]) but did not gain quality of life (QOL) (standarized mean difference, SMD 0.5, 95% CI [-0.13, 1.13]), with more adverse events (relative risk, RR 1.46, 95% CI [1.05, 2.04]), but no difference in deaths (RR 1.26, 95% CI [0.70, 2.27]). MA vs. no treatment: MA patients gained weight (MD 1.45 kg, 95% CI [0.15, 2.75]) but did not gain QOL (standardized mean difference 3.89 95% CI [-14, 6.28]). There was no increase in adverse events (RR 0.90, 95% CI [0.39, 2.08]) or deaths (RR 1.01, 95% CI [0.42, 2.45]). MA vs. active drugs: MA patients gained weight (MD 2.5 kg, 95% CI [0.37, 4.64]) but did not gain QOL (MD 0.20 95% CI [-0.02, 0.43]) and did not report an increase in adverse events (RR 1.05 95% CI [0.95, 1.16]) or in deaths (RR 1.53, 95% CI [1.02, 2.29]) Different doses of MA: in studies where lower doses of MA were compared with higher doses of MA, we did not find differences either in weight gain (MD -0.94 kg, 95% CI [-3.33, 1.45]), QOL (MD 0.31 95% CI [-0.19, 0.81]), or adverse events (RR 1.34, 95% CI [0.65, 2.76]). Thus, we cannot reach a conclusion for an optimal dose of MA.

Keywords: Anorexia; Appetite Stimulants; Cachexia; Megestrol Acetate; Randomized Controlled Trials; Systematic Review.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart. MA, megestrol acetate.
Figure 2
Figure 2
Risk of bias: summary.
Figure 3
Figure 3
Risk of bias graph.
Figure 4
Figure 4
Meta‐analysis of weight. CI, confidence interval; SD, standard deviation.
Figure 5
Figure 5
Meta‐analysis of the quality of life. CI, confidence interval; SD, standard deviation.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Berenstein EG, Ortiz Z. Megestrol acetate for the treatment of anorexia‐cachexia syndrome. Cochrane Database Syst Rev 2003. - PubMed
    1. Berenstein EG, Ortiz Z. Megestrol acetate for the treatment of anorexia‐cachexia syndrome. Cochrane Database Syst Rev 2005. - PubMed
    1. Ruiz Garcia V, Lopez‐Briz E, Carbonell Sanchis R, Gonzalvez Perales JL, Bort‐Marti S. Megestrol acetate for treatment of anorexia‐cachexia syndrome. Cochrane Database Syst Rev 2013;3:CD004310. - PMC - PubMed
    1. Nelson KA, Walsh D, Sheehan FA. The cancer anorexia‐cachexia syndrome. J Clin Oncol 1994;12:213–225. - PubMed
    1. Splinter TA. Cachexia and cancer: a clinician's view. Ann Oncol Off J Eur Soc Med Oncol ESMO 1992;3:25–27. - PubMed

LinkOut - more resources